Status:
COMPLETED
Buspirone as a Candidate Medication for Methamphetamine Abuse
Lead Sponsor:
University of Kentucky
Collaborating Sponsors:
National Institute on Drug Abuse (NIDA)
Conditions:
Methamphetamine Dependence
Methamphetamine Abuse
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
Methamphetamine use disorders are an unrelenting public health concern. Intensive research efforts have yielded behavioral interventions that reduce methamphetamine use, however, these interventions a...
Eligibility Criteria
Inclusion
- Lifetime methamphetamine use
Exclusion
- Abnormal screening outcome (e.g., ECG, blood chemistry result) that study physicians deem clinically significant
- Current or past histories of substance abuse or dependence that are deemed by the study physicians to interfere with study completion
- History of serious physical disease, current physical disease, impaired cardiovascular functioning, chronic obstructive pulmonary disease, history of seizure or current or past histories of serious psychiatric disorder that in the opinion of the study physician would interfere with study participation will be excluded from participation
- Females not currently using effective birth control
- Contraindications to methamphetamine or buspirone
Key Trial Info
Start Date :
April 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2017
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT01843205
Start Date
April 1 2013
End Date
March 1 2017
Last Update
February 7 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Kentucky Medical Center
Lexington, Kentucky, United States, 40536